Compositions that specifically bind to colorectal cancer cells and methods of using the same
CA 2299630 C · Owner: Thomas Jefferson University · Inventors: Pearlman, Joshua M.; Parkinson, Scott J.; Barber, Michael T.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A unique transcription product, CRCA-1 and alternative translation products , generated therefrom are disclosed. The transcript and its translation products are markers for colorectal cells. Screening and diagnostic reagents kits and methods for metastasized colorectal cancer are disclosed as are reagents, kits and methods for identifying adenocarcinomas as colorectal in origin. Compounds, compositions and methods of treating patients with metastasized colorectal cancer and for imaging metastasized colorectal tumors in vivo are disclosed. Compositions and methods for delivering active compounds such as gene therapeutics and antisense compounds to colorectal cells are disclosed. …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 7, 1998 and granted January 8, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 7, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 7, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.